This article is more than 5 years old. Information may no longer be current.
Top five ophthalmology stories of August
Click Here to Manage Email Alerts
The rare solar eclipse that passed through the United States in August led ophthalmology-related news for the month, which also included FDA advancements and business updates.
Here are the five most read news stories published on Healio.com/OSN this month:
1. Staring at eclipse may cause solar retinopathy
Remember when you were a kid and you used a magnifying glass to concentrate the sun’s energy to burn paper? Solar retinopathy is like that except it is the fovea that is getting burned, according to one expert. Read more here.
2. Johnson & Johnson Vision to acquire TearScience
Johnson & Johnson Vision announced it will acquire TearScience through Abbott Medical Optics, its surgical vision operating company. Read more here.
Read Darrell E. White, MD’s blog on the acquisition here.
3. FDA responds to NDA for glaucoma drug
The FDA sent a complete response letter to Valeant Pharmaceuticals regarding the new drug application for the Bausch + Lomb latanoprostene bunod ophthalmic solution 0.024% product called Vyzulta. Read more here.
4. FDA gives orphan drug designation for retinitis pigmentosa gene therapy
The FDA has given orphan drug designation to a gene therapy product intended for treatment of X-linked retinitis pigmentosa. Read more here.
5. FDA receives reports of serious adverse events after triamcinolone, moxifloxacin compound injections
The FDA is warning clinicians about serious adverse events reported after intravitreal injections of triamcinolone and moxifloxacin compounded by Guardian Pharmacy Services in Dallas. Read more here.